TRAVERE THERAPEUTICS INC (TVTX) Fundamental Analysis & Valuation

NASDAQ:TVTX • US89422G1076

Current stock price

28.03 USD
+0.23 (+0.83%)
At close:
28.03 USD
0 (0%)
After Hours:

This TVTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. TVTX Profitability Analysis

1.1 Basic Checks

  • In the past year TVTX has reported negative net income.
  • In the past year TVTX had a positive cash flow from operations.
  • In the past 5 years TVTX always reported negative net income.
  • In the past 5 years TVTX reported 4 times negative operating cash flow.
TVTX Yearly Net Income VS EBIT VS OCF VS FCFTVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of TVTX (-4.22%) is better than 85.91% of its industry peers.
  • TVTX has a better Return On Equity (-22.25%) than 80.50% of its industry peers.
Industry RankSector Rank
ROA -4.22%
ROE -22.25%
ROIC N/A
ROA(3y)-24.15%
ROA(5y)-27.41%
ROE(3y)-207.33%
ROE(5y)-266.16%
ROIC(3y)N/A
ROIC(5y)N/A
TVTX Yearly ROA, ROE, ROICTVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • TVTX's Gross Margin of 97.89% is amongst the best of the industry. TVTX outperforms 96.91% of its industry peers.
  • TVTX's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.51%
GM growth 5Y0.2%
TVTX Yearly Profit, Operating, Gross MarginsTVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TVTX Health Analysis

2.1 Basic Checks

  • TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TVTX has more shares outstanding
  • The number of shares outstanding for TVTX has been increased compared to 5 years ago.
  • The debt/assets ratio for TVTX has been reduced compared to a year ago.
TVTX Yearly Shares OutstandingTVTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
TVTX Yearly Total Debt VS Total AssetsTVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • TVTX has an Altman-Z score of 0.75. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TVTX (0.75) is better than 61.58% of its industry peers.
  • TVTX has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 2.71, TVTX is not doing good in the industry: 79.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF N/A
Altman-Z 0.75
ROIC/WACCN/A
WACC8.14%
TVTX Yearly LT Debt VS Equity VS FCFTVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M

2.3 Liquidity

  • A Current Ratio of 2.74 indicates that TVTX has no problem at all paying its short term obligations.
  • The Current ratio of TVTX (2.74) is worse than 67.95% of its industry peers.
  • A Quick Ratio of 2.70 indicates that TVTX has no problem at all paying its short term obligations.
  • TVTX has a worse Quick ratio (2.70) than 66.02% of its industry peers.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.7
TVTX Yearly Current Assets VS Current LiabilitesTVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TVTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 92.68% over the past year.
  • TVTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 110.46%.
  • Measured over the past years, TVTX shows a quite strong growth in Revenue. The Revenue has been growing by 19.87% on average per year.
EPS 1Y (TTM)92.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.11%
Revenue 1Y (TTM)110.46%
Revenue growth 3Y32.28%
Revenue growth 5Y19.87%
Sales Q2Q%73.41%

3.2 Future

  • Based on estimates for the next years, TVTX will show a very strong growth in Earnings Per Share. The EPS will grow by 99.13% on average per year.
  • Based on estimates for the next years, TVTX will show a very strong growth in Revenue. The Revenue will grow by 24.73% on average per year.
EPS Next Y195.54%
EPS Next 2Y197.6%
EPS Next 3Y116.67%
EPS Next 5Y99.13%
Revenue Next Year38.34%
Revenue Next 2Y35.18%
Revenue Next 3Y29.22%
Revenue Next 5Y24.73%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TVTX Yearly Revenue VS EstimatesTVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
TVTX Yearly EPS VS EstimatesTVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. TVTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 97.79, the valuation of TVTX can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TVTX indicates a rather cheap valuation: TVTX is cheaper than 88.61% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of TVTX to the average of the S&P500 Index (23.83), we can say TVTX is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 97.79
TVTX Price Earnings VS Forward Price EarningsTVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVTX Per share dataTVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as TVTX's earnings are expected to grow with 116.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y197.6%
EPS Next 3Y116.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TVTX Dividend Analysis

5.1 Amount

  • No dividends for TVTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TVTX Fundamentals: All Metrics, Ratios and Statistics

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (3/16/2026, 4:10:04 PM)

After market: 28.03 0 (0%)

28.03

+0.23 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)04-29
Inst Owners111.01%
Inst Owner Change-0.49%
Ins Owners0.88%
Ins Owner Change4.53%
Market Cap2.59B
Revenue(TTM)490.73M
Net Income(TTM)-25.55M
Analysts84.76
Price Target43.57 (55.44%)
Short Float %16.37%
Short Ratio6.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)178.51%
Min EPS beat(2)124.93%
Max EPS beat(2)232.09%
EPS beat(4)4
Avg EPS beat(4)106.4%
Min EPS beat(4)14.67%
Max EPS beat(4)232.09%
EPS beat(8)4
Avg EPS beat(8)39.94%
EPS beat(12)6
Avg EPS beat(12)-30.57%
EPS beat(16)7
Avg EPS beat(16)-27.51%
Revenue beat(2)1
Avg Revenue beat(2)20.56%
Min Revenue beat(2)-10.61%
Max Revenue beat(2)51.72%
Revenue beat(4)3
Avg Revenue beat(4)14.67%
Min Revenue beat(4)-10.61%
Max Revenue beat(4)51.72%
Revenue beat(8)5
Avg Revenue beat(8)7.63%
Revenue beat(12)8
Avg Revenue beat(12)1.51%
Revenue beat(16)9
Avg Revenue beat(16)-8.11%
PT rev (1m)1.53%
PT rev (3m)2.93%
EPS NQ rev (1m)-48.1%
EPS NQ rev (3m)-48.1%
EPS NY rev (1m)-57.57%
EPS NY rev (3m)-57.58%
Revenue NQ rev (1m)2.45%
Revenue NQ rev (3m)2.45%
Revenue NY rev (1m)0.57%
Revenue NY rev (3m)0.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 97.79
P/S 5.27
P/FCF N/A
P/OCF 68.43
P/B 22.52
P/tB 2693.22
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)0.29
Fwd EY1.02%
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)0.41
OCFY1.46%
SpS5.32
BVpS1.24
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.22%
ROE -22.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.89%
FCFM N/A
ROA(3y)-24.15%
ROA(5y)-27.41%
ROE(3y)-207.33%
ROE(5y)-266.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.51%
GM growth 5Y0.2%
F-Score7
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.74%
Cap/Sales 11.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.74
Quick Ratio 2.7
Altman-Z 0.75
F-Score7
WACC8.14%
ROIC/WACCN/A
Cap/Depr(3y)145.93%
Cap/Depr(5y)122.97%
Cap/Sales(3y)28.12%
Cap/Sales(5y)21.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.11%
EPS Next Y195.54%
EPS Next 2Y197.6%
EPS Next 3Y116.67%
EPS Next 5Y99.13%
Revenue 1Y (TTM)110.46%
Revenue growth 3Y32.28%
Revenue growth 5Y19.87%
Sales Q2Q%73.41%
Revenue Next Year38.34%
Revenue Next 2Y35.18%
Revenue Next 3Y29.22%
Revenue Next 5Y24.73%
EBIT growth 1Y75.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year474.67%
EBIT Next 3Y159.8%
EBIT Next 5Y99.22%
FCF growth 1Y93.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y115.91%
OCF growth 3YN/A
OCF growth 5YN/A

TRAVERE THERAPEUTICS INC / TVTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TRAVERE THERAPEUTICS INC (TVTX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to TVTX.


What is the valuation status for TVTX stock?

ChartMill assigns a valuation rating of 3 / 10 to TRAVERE THERAPEUTICS INC (TVTX). This can be considered as Overvalued.


How profitable is TRAVERE THERAPEUTICS INC (TVTX) stock?

TRAVERE THERAPEUTICS INC (TVTX) has a profitability rating of 3 / 10.